CalciMedica Inc(CALC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 7:54 PM ET (Korea 11/7 09:54)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.79 | Insider Own | 39.39% | Shs Outstand | 6.2M | Perf Week | -6.85% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -75.69% | Insider Trans | 10.21% | Shs Float | 4.1M | Perf Month | 4.62% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -1.27 | Inst Own | 34.19% | Short Float | 1.49% | Perf Quarter | -58.73% |
| Income | -0.02B | P/S | - | EPS this Y | 69.37% | Inst Trans | 22.62% | Short Ratio | 0.76 | Perf Half Y | -56.76% |
| Sales | 0.00B | P/B | 1.52 | EPS next 5Y | 36.9% | ROA | -110.1% | Short Interest | 0.06M | Perf YTD | -95.87% |
| Book/sh | 0.9 | P/C | 0.5 | EPS past 3/5Y | 89.18% 38.92% | ROE | -365.7% | 52W High | -96.22% ($36.00) | Perf Year | -91.11% |
| Cash/sh | 2.73 | P/FCF | - | Sales past 3/5Y | - | ROIC | -144.36% | 52W Low | 36% ($1.00) | Perf 3Y | -91.5% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 15.38% | Gross Margin | - | Volatility(W/M) | 15.5% 14.52% | Perf 5Y | -99.4% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.58 | EPS Q/Q | -12.66% | Profit Margin | - | RSI (14) | 46.15 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.58 | Sales Q/Q | - | SMA20 | 6.73% ($1.27) | Beta | 0.8 | Target Price | $37.5 |
| Payout | - | Debt/Eq | 1.67 | Earnings | 2026/8/11 | SMA50 | -15.98% ($1.62) | Rel Volume | 0.25 | Prev Close | $1.3 |
| Employees | 16 | LT Debt/Eq | 1.67 | EPS/Sales Surpr. | -57.89% - | SMA200 | -59.86% ($3.39) | Avg Volume(3M) | 0.08M | Price | $1.36 |
| IPO | 2020/9/25 | Option/Short | No/Yes | Trades | 195 | Volume | 20,569 | Change | 4.62% |
🧪 This is a clinical-stage biotech developing a new drug that blocks calcium signaling (CRAC channels) in immune cells to reduce acute inflammation and organ damage. Its lead pipeline is the intravenous CRAC inhibitor Auxora (zegocractin), targeting critically ill patient groups with indications including acute pancreatitis (AP), acute kidney injury (AKI), and pulmonary arterial hypertension (PAH). It is a micro-cap company listed on NASDAQ.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual. That is 25% of its average volume.
CALC has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +69.4% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.4%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 34.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #510 of 597 in the industry
Based on market cap of $9M.
MTVA#508 MetaVia Inc $9M PER - 
PHIO#509 Phio Pharmaceuticals Corp $9M PER - CALC#510 CalciMedica Inc $9M PER - 
MBRX#511 Moleculin Biotech Inc $9M PER - 
INAB#512 IN8bio Inc $9M PER - 
FAQ
What kind of company is CALC?
CALC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CALC?
The market cap of CALC is approximately $9M, ranking 5,437 within its sector.
What is the 52-week high and low for CALC?
CALC has recorded a 52-week high of $36.00 and a low of $1.00.
